The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast.

Official Title

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Further Details

  • Primary Outcomes: exacerbation rate; FEV1.
  • Secondary Outcomes: other spirometry parameters; COPD symptoms; safety and tolerability of roflumilast.

Study Start

February 2006

Eligibility & Criteria

  • Ages Eligible for Study: 40 Years and above
  • Genders Eligible for Study: Both

Main Inclusion Criteria:

  • COPD patients who have exacerbations
  • FEV1/FVC ratio (post-bronchodilator) 70%
  • FEV1 (post-bronchodilator) 50% of predicted

Main Exclusion Criteria:

  • COPD exacerbation not resolved at first baseline visit
  • Diagnosis of asthma and/or other relevant lung disease

Total Enrolment

1500 (expected)

Contact Details

ALTANA Pharma, Cities in Australia, Australia; Recruiting

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.